Can you provide the correct prescription classification and detailed dosing instructions for Wegovy (semaglutide) 1.5 mg tablet, including timing, duration, quantity, and refill for titration?

Critical Prescription Error: Wegovy is NOT an Oral Tablet

This prescription is fundamentally incorrect. Wegovy (semaglutide) is ONLY available as a subcutaneous injection, NOT as an oral tablet. The prescription as written cannot be filled and represents a serious medication error 1.

Correct Wegovy Formulation and Dosing

Route of Administration

• Wegovy is administered subcutaneously (under the skin) once weekly using prefilled, single-dose pens 1
• Injection sites: abdomen, thigh, or upper arm 1
• Can be given any time of day, with or without meals 1

Correct Dose Titration Schedule

Wegovy requires a mandatory 4-week titration schedule to minimize gastrointestinal side effects 1:

• Weeks 1-4: 0.25 mg subcutaneously once weekly
• Weeks 5-8: 0.5 mg subcutaneously once weekly
• Weeks 9-12: 1.0 mg subcutaneously once weekly
• Weeks 13-16: 1.7 mg subcutaneously once weekly
• Week 17 onward: 2.4 mg subcutaneously once weekly (recommended maintenance dose) OR 1.7 mg once weekly (alternative maintenance dose) 1

Correct Initial Prescription

For the first month:

• Dispense: Wegovy 0.25 mg/0.5 mL prefilled pen, 4 pens (one per week)
• Instructions: Inject 0.25 mg subcutaneously once weekly on the same day each week
• Refills: 0 (patient must return for dose escalation assessment)

Important Clarification: Oral Semaglutide Exists BUT is a Different Product

Oral semaglutide (Rybelsus) is FDA-approved ONLY for type 2 diabetes, NOT for weight management 2. The oral formulation:

• Requires fasting administration: take with ≤120 mL water at least 30 minutes before first food, beverage, or other medications 2, 3
• Maximum approved dose for diabetes: 14 mg daily 2
• Has only ~1% bioavailability (vs. 89% for subcutaneous) 4
• Is NOT interchangeable with Wegovy 1

Critical Safety Considerations

Contraindications 1

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity to semaglutide

Monitoring Requirements 1

• In patients with type 2 diabetes: Monitor blood glucose before starting and during treatment (risk of hypoglycemia when combined with insulin or sulfonylureas) 5, 6, 7
• Monitor for gastrointestinal symptoms during titration 8, 6, 8
• Assess efficacy at 3-4 months: if <5% weight loss, consider discontinuation 9, 6

Common Pitfalls in Real-World Use

Real-world data shows significant deviations from approved dosing 10, 11, 12:

• Only 13-25% of patients reach the 2.4 mg maintenance dose 10, 12
• 33-48% remain on 1.0 mg dose long-term 10, 12
• 46-48% discontinue within 5 months 11, 12
• Few patients follow the recommended 4-week titration intervals 10, 12

However, the FDA-approved titration schedule should be followed to minimize adverse effects and optimize outcomes 1.

When Patient Returns for Titration

Schedule follow-up visits every 4 weeks during dose escalation 9, 6:

• Assess tolerability and gastrointestinal side effects
• If patient cannot tolerate current dose, consider delaying escalation by 4 weeks 1
• Advance to next dose level if tolerating well
• Continue until reaching maintenance dose (2.4 mg preferred, 1.7 mg acceptable) 1